Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Kobylecki

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
BMJ Open|July 29, 2025
Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UKRobert Durcan, Hugo Paula, Boyd C P Ghosh, et al.
Brain Communications|March 12, 2025
Distinct spatiotemporal atrophy patterns in corticobasal syndrome are associated with different underlying pathologiesWilliam J Scotton, Cameron Shand, Emily G Todd, et al.
Medrxiv : the Preprint Server for Health Sciences|January 2, 2026
Identification of common variants influencing risk of the three-repeat tauopathy Pick's disease: a genome wide association studyWilliam J Scotton, Rebecca R Valentino, Alejandro Martinez-Carrasco, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2021
Dissecting the Phenotype and Genotype of PLA2G6-Related ParkinsonismFrancesca Magrinelli, Sahil Mehta, Giulia Di Lazzaro, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 20, 2024
Evaluation of Cerebrospinal Fluid α-Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal SyndromeDavid P Vaughan, Riona Fumi, Marte Theilmann Jensen, et al.
Annals of Neurology|July 29, 2025
Exenatide Once Weekly in the Treatment of Patients with Multiple System AtrophyNirosen Vijiaratnam, Christine Girges, Martin Wiegand, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 16, 2026
Biomarkers of Leucine-Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear PalsyLouise-Kristine Nielsen, Joshua L I Frost, David P Vaughan, et al.
Brain : a Journal of Neurology|March 28, 2023
Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trialsDuncan Street, Edwin Jabbari, Alyssa Costantini, et al.
JAMA Neurology|December 21, 2019
Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal SyndromeEdwin Jabbari, Negin Holland, Viorica Chelban, et al.
The Lancet. Neurology|June 20, 2025
Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort studyChristina D Orrú, David P Vaughan, Nirosen Vijiaratnam, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
BMJ Open|July 29, 2025
Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UKRobert Durcan, Hugo Paula, Boyd C P Ghosh, et al.
Brain Communications|March 12, 2025
Distinct spatiotemporal atrophy patterns in corticobasal syndrome are associated with different underlying pathologiesWilliam J Scotton, Cameron Shand, Emily G Todd, et al.
Medrxiv : the Preprint Server for Health Sciences|January 2, 2026
Identification of common variants influencing risk of the three-repeat tauopathy Pick's disease: a genome wide association studyWilliam J Scotton, Rebecca R Valentino, Alejandro Martinez-Carrasco, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2021
Dissecting the Phenotype and Genotype of PLA2G6-Related ParkinsonismFrancesca Magrinelli, Sahil Mehta, Giulia Di Lazzaro, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 20, 2024
Evaluation of Cerebrospinal Fluid α-Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal SyndromeDavid P Vaughan, Riona Fumi, Marte Theilmann Jensen, et al.
Annals of Neurology|July 29, 2025
Exenatide Once Weekly in the Treatment of Patients with Multiple System AtrophyNirosen Vijiaratnam, Christine Girges, Martin Wiegand, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 16, 2026
Biomarkers of Leucine-Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear PalsyLouise-Kristine Nielsen, Joshua L I Frost, David P Vaughan, et al.
Brain : a Journal of Neurology|March 28, 2023
Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trialsDuncan Street, Edwin Jabbari, Alyssa Costantini, et al.
JAMA Neurology|December 21, 2019
Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal SyndromeEdwin Jabbari, Negin Holland, Viorica Chelban, et al.
The Lancet. Neurology|June 20, 2025
Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort studyChristina D Orrú, David P Vaughan, Nirosen Vijiaratnam, et al.
Pageof 11